Report of Foreign Issuer (6-k)
12 February 2019 - 10:09PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 11, 2019
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo
Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 11 February 2019
– On 1 February
2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European
Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation No 1052/2016 of 8 March 2016, also referred
to as the Safe Harbour Regulation. This programme is part of the overall share repurchase programme of up to DKK 15 billion to
be executed during a 12-month period beginning 1 February 2019.
Under the programme initiated 1 February 2019, Novo Nordisk will repurchase
B shares for an amount up to DKK 2.7 billion in the period from 1 February 2019 to 1 May 2019.
Since the announcement of the programme, the following transactions have been
made:
|
|
Number of
B shares
|
|
|
Average
purchase price
|
|
|
Transaction
value, DKK
|
|
1 February 2019
|
|
|
139,000
|
|
|
|
316.44
|
|
|
|
43,985,459
|
|
4 February 2019
|
|
|
140,000
|
|
|
|
315.94
|
|
|
|
44,231,972
|
|
5 February 2019
|
|
|
140,000
|
|
|
|
318.35
|
|
|
|
44,569,329
|
|
6 February 2019
|
|
|
140,000
|
|
|
|
317.90
|
|
|
|
44,505,575
|
|
7 February 2019
|
|
|
140,000
|
|
|
|
320.97
|
|
|
|
44,935,770
|
|
8 February 2019
|
|
|
140,000
|
|
|
|
320.90
|
|
|
|
44,926,110
|
|
Accumulated under the programme
|
|
|
839,000
|
|
|
|
|
|
|
|
267,154,215
|
|
The details for each
transaction made under the share repurchase programme are published on novonordisk.com.
Transactions related to Novo Nordisk’s incentive programmes have
resulted in a net transfer from Novo Nordisk of 2,349,164 B shares in the period from 1 February 2019 to
Page 2 of 2
8 February 2019. The shares in these transactions were not part of
the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 58,159,766
B shares of DKK 0.20, corresponding to 2.4% of the share capital, as treasury shares. The total amount of A and B shares in the
company is 2,450,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15
billion during a 12-month period beginning 1 February 2019. As of 8 February 2019, Novo Nordisk has since 1 February 2019 repurchased
a total of 839,000 B shares at an average share price of DKK 318.42 per B share equal to a transaction value of DKK 267,154,215.
Novo Nordisk is
a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us
experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious
chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 80 countries and markets its products
in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York
Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media:
|
|
|
Anne Margrethe Hauge
|
+45 4442 3450
|
amhg@novonordisk.com
|
Ken Inchausti (US)
|
+1 609 240 9429
|
kiau@novonordisk.com
|
|
|
|
Investors
:
|
|
|
Peter Hugreffe Ankersen
|
+45 3075 9085
|
phak@novonordisk.com
|
Anders Mikkelsen
|
+45 3079 4461
|
armk@novonordisk.com
|
Valdemar Borum Svarrer
|
+45 3079 0301
|
jvls@novonordisk.com
|
Kristoffer Due Berg
|
+45 3079 2849
|
krdb@novonordisk.com
|
Ann Søndermølle Rendbæk
|
+45 3075 2253
|
arnd@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 8 / 2019
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: February 11, 2019
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024